Insight

If mRNA therapeutics are likened to confidential biological dispatches destined for the interior of cells, lipid nanoparticles (LNPs) act as elite escorts that navigate a host of biological barriers. Without LNPs, these molecular messages cannot even begin their journey.

This reliance stems not from arbitrary technical preferences, but from the inherent physicochemical properties of mRNA and the defensive mechanisms of the human body. Comprehending why mRNA is dependent on LNPs lays the foundation for understanding the entire mRNA therapeutic platform.

mRNA is a single-stranded nucleic acid with extreme chemical lability. Ubiquitous ribonucleases (RNases) present in blood, interstitial fluid, on cell surfaces and even in ambient air rapidly degrade unprotected mRNA within minutes. These enzymes are a natural defense system evolved by the human body to eliminate foreign RNA.

Beyond enzymatic degradation, the molecular structure of mRNA is inherently unstable. The 2′-hydroxyl group on its ribose ring renders the phosphodiester bonds susceptible to hydrolytic cleavage. Even in enzyme-free environments at room temperature, naked mRNA degrades completely within hours. Such inherent instability makes direct oral administration or simple injection of bare mRNA unfeasible, unlike small-molecule drugs.

The primary function of LNPs is to provide robust physical protection. mRNA is encapsulated within the aqueous core of nanoparticles, surrounded by a dense lipid bilayer that shields the payload from RNases and other degradative factors. This protective effect persists throughout systemic circulation until LNPs reach target cells.

Even if mRNA evades degradation, it faces a second insurmountable obstacle: inability to cross cell membranes. The cell membrane is a selectively permeable phospholipid bilayer that only permits passage of specific small molecules. mRNA is large (composed of thousands of nucleotides) and carries a strong negative charge.

Since the cell membrane is also negatively charged, electrostatic repulsion prevents naked mRNA from approaching or penetrating cells. Unencapsulated mRNA is confined to the extracellular space and can never access the intracellular machinery required for protein synthesis.

LNPs resolve this issue via their specialized formulation. A key component, ionizable lipids, remains electrically neutral at physiological pH, minimizing electrostatic repulsion with cell membranes. Meanwhile, the optimal particle size of LNPs (80–100 nanometers) enables cellular uptake through endocytosis. In essence, LNPs package mRNA into a cargo that cells readily internalize.

Once internalized via endocytosis, LNPs are sequestered inside endosomal vesicles rather than directly released into the cytoplasm. Endosomes gradually acidify and eventually fuse with lysosomes — the cellular digestive compartments packed with hydrolytic enzymes that break down nucleic acids. If mRNA fails to escape the endosomal compartment, it will be fully degraded, rendering the entire delivery process futile.

Endosomal escape represents the most sophisticated design feature of LNPs. The pKa value of ionizable lipids is precisely tuned to 6.0–6.5. In the acidic microenvironment of endosomes, these lipids become positively charged. The resulting electrostatic interactions disrupt the endosomal membrane, releasing mRNA into the cytoplasm, where ribosomes carry out protein synthesis. Without this escape capability, LNPs would merely serve as permanent traps.

Upon reaching the cytoplasm, mRNA still faces threats from the host innate immune system. Pattern recognition receptors within cells are evolved to detect foreign RNA such as viral genomes. Activation of these receptors triggers potent inflammatory responses and suppresses protein translation.

Early mRNA research was hampered by severe immunogenicity associated with in vitro transcribed mRNA. A landmark discovery by Katalin Karikó and Drew Weissman in 2005 revolutionized the field: substituting uridine with pseudouridine markedly reduces the immunogenicity of mRNA. Additionally, polyethylene glycol (PEG)-conjugated lipids in LNPs confer “stealth” properties to evade immune surveillance, while encapsulation limits direct contact between mRNA and intracellular immune sensors.

Individual strategies exist to address each aforementioned hurdle: RNase inhibitors slow degradation, electroporation facilitates cellular entry, and chemical modifications mitigate immune reactions. However, these standalone approaches cannot be integrated into safe, clinically viable delivery systems for human use.

The unparalleled value of LNPs lies in their capacity to resolve all delivery challenges via a single platform: protecting mRNA from degradation, facilitating cellular uptake, enabling endosomal escape, lowering immunogenicity, and supporting large-scale manufacturing and clinical translation. LNPs perform irreplaceable functions across every stage of the delivery cascade.

Naked mRNA possesses virtually no therapeutic value in vivo. Intravenously administered unencapsulated mRNA is degraded by RNases within minutes. Even if locally injected mRNA occasionally enters cells, it is trapped and degraded in endosomes. Rare molecules that escape into the cytoplasm may trigger robust immune responses that inhibit protein expression.

Before the maturation of LNP technology, the development of mRNA therapeutics stagnated. Advances in LNP delivery transformed mRNA from a laboratory research tool into a clinically applicable therapeutic platform. The 2023 Nobel Prize in Physiology or Medicine honored Katalin Karikó and Drew Weissman for discovering nucleoside modification to reduce mRNA immunogenicity. Equally instrumental, LNPs translated this fundamental breakthrough into life-saving vaccines used worldwide.

The relationship between mRNA and LNPs is far beyond that of an active pharmaceutical ingredient and an excipient — they form an inseparable partnership. Without LNPs, mRNA cannot survive in vivo, penetrate cells, escape endosomes, or be translated by ribosomes. mRNA carries therapeutic genetic information, while LNPs create a functional pathway for this information to reach its destination accurately.

Understanding the necessity of LNPs for mRNA delivery unlocks the core logic of mRNA therapeutics. mRNA is not a conventional drug, but a set of biological instructions that require protection, delivery and controlled release. LNPs are not trivial formulation additives, but sophisticated vehicles that guide these genetic instructions through complex biological barriers.